MiCheck® testing for prostate cancer: quick, non-invasive, highly specific
MiCheck® is a blood test that uses our patented monoclonal antibody together with other biomarkers to estimate the risk of a patient having aggressive prostate cancer.
The MiCheck® test is designed to assist urologists in making the decision to recommend a patient has a biopsy or moves on to some form of active surveillance monitoring.
The problem in prostate cancer diagnosis
The PSA test is commonly used to detect prostate cancer however elevated PSA levels can be caused by factors other than prostate cancer.
This results in six in ten men needlessly being subjected to an unnecessary needle biopsy.
- Are traumatic, painful, and potentially lead to infection, which can make a man reluctant to see if they really need treatment for prostate cancer;
- Add to health care costs, because biopsies are expensive.
The estimated over-diagnosis using PSA for population screening in the USA (US Cancer Screening 2018) is 23-29% for Caucasian men and 35-44% for African-American men.
The MiCheck® Solution for prostate cancer diagnosis
The MiCheck® test will assist urologists in making the decision to biopsy by estimating the risk of the patient having aggressive prostate cancer. Being a simple blood test MiCheck® is less invasive than a prostate biopsy and also returns an answer to the physician on the patient’s cancer status within 48 hours. The test works by measuring several protein biomarkers including a proprietary marker owned by Minomic called Glypican -1.
Why is MiCheck® the missing step in prostate cancer diagnosis?
- It’s more specific than a PSA test – so a urologist can tell if a biopsy is really needed.
- Patients and their physicians will have confidence about what to do next. Patients who should get treatment for prostate cancer will get it sooner, and men whose MiCheck® results are negative can be monitored every year or two.
Learn more about the development of our prostate cancer diagnostic MiCheck® test – click here.